Opioid-Induced Constipation Market

• The Opioid Induced Constipation market is expected to strengthen as awareness of the disease increases and more effective interventions are being developed.
• The leading Opioid Induced Constipation Companies in the market include HealthCore Inc, Forest Laboratories, Ironwood Pharamceuticals Inc, Progenics Pharmaceuticals Inc, AstraZeneca, Nektar Therapeutics, Apices Soluciones SL, Shionogi Inc, Mundipharma Research GmbH & Co KG, QuintilesIMS Inc, Alkermes Inc, Theravance Biopharma, Cubist Pharmaceuticals LLC, Pfizer, BioGaia Pharma AB, Valinor Pharma LLC, Takeda, and others

Request for unlocking the CAGR of Opioid Induced Constipation Market

DelveInsight’s “Opioid Induced Constipation– Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of Opioid Induced Constipation, historical and forecasted epidemiology as well as the Opioid Induced Constipation market trends in the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.

The Opioid Induced Constipation market report provides current treatment practices, emerging drugs, Opioid Induced Constipation market share of the individual therapies, and current and forecasted Opioid Induced Constipation market size from 2019 to 2032, segmented by seven major markets. The report also covers current Opioid Induced Constipation treatment practices/algorithms and Opioid Induced Constipation unmet needs to curate the best of the opportunities and assess the underlying potential of the market.

Opioid Induced Constipation Treatment Market

The DelveInsight’s Opioid Induced Constipation market report gives a thorough understanding of Opioid Induced Constipation by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

The term Opioid-induced Constipation (OIC) is defined as a change from baseline in bowel habits after initiation of opioids that includes any of the following symptoms: reduced bowel movement frequency, development or worsening of straining to pass stool, a sense of incomplete rectal evacuation, and harder stool consistency. Opioid-induced constipation (OIC) accounts from over 40% to 60% in patients without cancer receiving opioid. Studies showed that patients who developed OIC were more likely to be older, female, and unemployed.Opioid-induced constipation (OIC) occurs primarily via activation of enteric μ-receptors, which results in increased tonic non-propulsive contractions in the small and large intestine, increased colonic fluid absorption, and stool desiccation.

Opioid Induced Constipation Diagnosis

The Rome IV diagnostic criteria is widely used for the diagnosis of functional constipation.The Rome IV criteria include two of following for the last 3 months:

• Hard stools in at least 25 percent of defecations
• Straining in at least 25 percent of defecation
• A sensation of incomplete evacuation in at least 25 percent of defecations
• Less than 3 bowel movements per week
• Use of manual measures to help move or remove the stools from the rectum

Additionally, the Bristol Stool Scale can be used to classify the form of feces into seven categories. Type 1 and 2 show hard stools while types 3 and 4 are normal. Individuals with loose stools (types 5 through 7) tend to have diarrhea.

Imaging is not routinely done when patients present with constipation. Physicians should look out for alarm symptoms including weight loss, positive fecal occult blood tests, iron deficiency anemia, and a family history of colon cancer.

Opioid Induced Constipation Treatment

The initial treatment of Opioid Induced Constipation involves laxatives and stool softener. When laxatives and stool softeners aren't enough, medical practioner prescribes a medication that are made for people who have constipation because of opioids. These medication work by blocking the effects that the drugs have on your gut such as: Lubiprostone, Methynaltrexone, Naldemedine, Naloxegol. Naloxegol and naldemedine are both approved for treatment of OIC in patients with non-cancer pain. Alvimopan has only been approved to treat recalcitrant cases of postoperative ileus. In the United States, lubiprostone is approved for treatment of OIC in patients with non-cancer pain and those with cancer.

Opioid Induced Constipation Epidemiology

The Opioid Induced Constipation epidemiology section provides insights into historical and current Opioid Induced Constipation patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Opioid Induced Constipation report also provides the diagnosed patient pool, their trends and assumptions undertaken.

Key findings

The Opioid Induced Constipation epidemiology covered in the report provides historical as well as forecasted Opioid Induced Constipation epidemiology [segmented as Prevalence of Opioid Induced Constipation, Gender based Prevalent cases of Opioid Induced Constipation, Prevalence of chronic non-cancer pain and cancer pain] in the 7MM covering the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan from 2019 to 2032.

Country-wise Opioid Induced Constipation Epidemiology

The epidemiology segment also provides the Opioid Induced Constipation epidemiology data and findings across the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.

Opioid Induced Constipation Drug Chapters

The drug chapter segment of the Opioid Induced Constipation report encloses the detailed analysis of Opioid Induced Constipation marketed drugs and late-stage (Phase III and Phase II) Opioid Induced Constipation pipeline drugs. It also helps understand the Opioid Induced Constipation clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Opioid Induced Constipation Marketed Drugs

Naloxegol and naldemedine are both approved for treatment of OIC in patients with non-cancer pain. Alvimopan has only been approved to treat recalcitrant cases of postoperative ileus. In the United States, lubiprostone is approved for treatment of OIC in patients with non-cancer pain and those with cancer.

Note: Detailed Current therapies assessment will be provided in the full report

Opioid-Induced Constipation Emerging Drugs

BGP345A: BioGaia Pharma

BGP345A is being developed for the treatment of constipation in patients receiving opioid therapy for prescribed pain treatment. BGP345A has potential to provide a novel and effective approach to restoring gut motility where treatment is currently suboptimal.

Currently, the drug is in Phase II clinical trial for randomized placebo-controlled study to assess safety and preliminary efficacy of BGP345A in patients with constipation due to the use of opioid-based medications for the management of chronic non cancer pain.

Linaclotide: Ironwood/Forest Laboratories

Linaclotide is a guanylate cyclase-c agonist that increases smooth muscle contraction and promotes bowel movement. Currently, the drug is in Phase II for multicenter, randomized, double-blind, placebo-controlled, parallel group trial of linaclotide administered orally for 8 weeks to adult outpatients with opioid-induced constipation receiving chronic opioid treatment for non-cancer pain.

Note: Detailed emerging therapies assessment will be provided in the full report

Opioid Induced Constipation Market Outlook

The initial treatment of Opioid Induced Constipation involves laxatives and stool softener. Stool softeners make hard, dry waste easier to pass out of your body while laxatives help your bowels move the stools out. When laxatives and stool softeners aren't enough, doctors prescribe a medication that are made for people who have constipation because of opioids. These meds work by blocking the effects that the drugs have on your gut such as: Lubiprostone, Methynaltrexone, Naldemedine, and Naloxegol.

Naloxegol and naldemedine are both approved for treatment of OIC in patients with non-cancer pain. Alvimopan has only been approved to treat recalcitrant cases of postoperative ileus. In the United States, lubiprostone is approved for treatment of OIC in patients with non-cancer pain and those with cancer.

According to DelveInsight, the Opioid Induced Constipation market in 7MM is expected to witness a major change in the study period 2019–2032.

Key findings

This section includes a glimpse of the Opioid Induced Constipation market in 7MM.

The United States: Opioid Induced Constipation Market Outlook

This section provides the total Opioid Induced Constipation market size and market size by therapies in the United States.

EU4 and the UK Countries: Opioid Induced Constipation Market Outlook

The Total Opioid Induced Constipation market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan: Opioid Induced Constipation Market Outlook

The total Opioid Induced Constipation market size and market size by therapies in Japan are also mentioned.

Opioid Induced Constipation Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Opioid Induced Constipation market or expected to get launched in the market during the study period 2019–2032. The analysis covers Opioid Induced Constipation market uptake by drugs, patient uptake by therapies, and sales of each drug.

This will help in understanding the Opioid Induced Constipation drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Opioid Induced Constipation Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Opioid Induced Constipation’s key players involved in developing targeted therapeutics.

Developmental Activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for Opioid Induced Constipation emerging therapies.

Opioid Induced Constipation Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Opioid Induced Constipation domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Opioid Induced Constipation market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Opioid Induced Constipation unmet needs.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Opioid Induced Constipation market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Opioid Induced Constipation Market Report Scope

• Descriptive overview of Opioid Induced Constipation, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the Opioid Induced Constipation epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and emerging therapies for Opioid Induced Constipation, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
• Exhaustive analysis of the Opioid Induced Constipation market; historical and forecasted covering drug outreach in the 7MM
• Detailed patient-based Opioid Induced Constipation market forecasting determines the trends shaping and driving the global Opioid Induced Constipation market

Opioid Induced Constipation Market Report Highlights

• In the coming years, the Opioid Induced Constipation market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The Opioid Induced Constipation companies and academics are working to assess challenges and seek opportunities that could influence Opioid Induced Constipation R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Opioid Induced Constipation companies are involved in developing Opioid Induced Constipation therapies. The launch of emerging therapies will significantly impact the Opioid Induced Constipation market
• A better understanding of Opioid Induced Constipation pathogenesis will also contribute to the development of novel therapeutics for Opioid Induced Constipation
• Our in-depth analysis of the Opioid Induced Constipation pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed Opioid Induced Constipation clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Opioid Induced Constipation Report Insights

• Patient-Based Opioid Induced Constipation Market Forecasting
• Therapeutic approaches
• Opioid Induced Constipation pipeline analysis
• Opioid Induced Constipation market size and trends
• Opioid Induced Constipation market opportunities
• Impact of upcoming therapies

Opioid Induced Constipation Report Key Strengths

• 10 year forecast
• 7MM Coverage
• Opioid Induced Constipation epidemiology Segmentation
• Key cross competition
• KOL views
• Opioid Induced Constipation drugs uptake

Opioid Induced Constipation Report Assessment

• Current Opioid Induced Constipation treatment market practices
• Opioid Induced Constipation Unmet needs
• Opioid Induced Constipation pipeline drugs profiles
• Opioid Induced Constipation market attractiveness

Key Questions

Opioid Induced Constipation market insights:

• What would be the Opioid Induced Constipation market growth till 2032, and what will be the resultant market size in 2032?
• What was the Opioid Induced Constipation drug class share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the total Opioid Induced Constipation market size and market size by therapies across the 7MM during the forecast period (2023–2032)?
• What are the key findings of the market across 7MM, and which country will have the largest Opioid Induced Constipation market size during the forecast period (2023–2032)
• How would the unmet needs affect the Opioid Induced Constipation market dynamics and subsequent analysis of the associated trends?

Opioid Induced Constipation Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Opioid Induced Constipation?
• What is the historical and forecasted Opioid Induced Constipation patient pool in 7MM, and where can one observe the highest patient population and growth opportunities?
• What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, Spain), and the UK, and Japan?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for Opioid Induced Constipation in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Opioid Induced Constipation therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Opioid Induced Constipation and its status, along with the challenges faced?

Reasons to Buy

• The patient-based Opioid Induced Constipation market forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Opioid Induced Constipation market
• Organize sales and marketing efforts by identifying the best opportunities for Opioid Induced Constipation in the US, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors.